This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
RIPK3 / Receptor-interacting serine/threonine-protein kinase 3 · Western blot design guide
Design a Western Blot for RIPK3
Real validated RIPK3 Western blot protocols, expected-band and isoform facts, troubleshooting for weak or shifted signal, and recommended anti-RIPK3 WB antibodies. Everything you need to plan the experiment before you commit precious samples.
Evidence assembled September 2026 · For research use; verify linked source records and product datasheet before use
RIPK3 Western Blot Experimental Design Guide
Expected bands, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before running
| Expected band | ~56.9 kDa | |
| Gel | 12–15% (standard starting point) | |
| Negative control | Suggested KO / knockdown lysate |
Important caveats
Reasons your observed band may differ from the expected size.
| PTM | Phosphorylated + Ubl conjugation | |
| Caveat | Phosphorylation-state controls | |
| Gene-set association | MSigDB C7 membership | |
| Isoform | 3 isoform(s) |
Section 1
Real Curated RIPK3 Western Blot Protocols
The PA2242 protocol combines labelled catalog values with standard starting conditions. Published comparisons retain their own sample, reagent and detection scope.
| Sample / lysate | PANC, SW620, SKOV-3 (catalog PA2242) |
| Gel % | 12–15% (standard starting point) |
| Load | 20–30 µg total protein per lane; optimize for abundance (standard starting point) |
| Transfer | Standard semi-dry transfer; verify efficiency (standard starting point) |
| Membrane | 0.45 µm PVDF (standard starting point) |
| Blocking | 5% milk or 5% BSA in TBST (standard starting point) |
| Primary antibody | PA2242; use the WB datasheet starting dilution (standard starting point) |
| Primary incubation | Overnight at 4 °C (standard starting point) |
| Secondary antibody | Species-matched HRP conjugate at validated dilution (standard starting point) |
| Secondary incubation | 1 h at room temperature (standard starting point) |
| Wash | 3 × 5 min in TBST (standard starting point) |
| Detection | ECL; bracket exposures to avoid saturation (standard starting point) |
Section 2
What Is the Expected RIPK3 Western Blot Band Size?
RIPK3 is predicted at 56.9 kDa; splice isoforms and phosphorylation could affect migration, but no empirical band size or visible shift is established.
| Band near 56.9 kDa | Consistent with the predicted RIPK3 mass; confirm band identity. |
| Several bands at different positions | Could reflect isoforms 1, 2, and 3 if their migration differs; identity requires confirmation. |
| Doublet near the expected position | Could reflect different RIPK3 phosphorylation states; the pattern is not established by the site annotations alone. |
| Weaker band in a cytosolic fraction after influenza A infection | Could reflect the reported infection-dependent nuclear localization. |
💡Expected RIPK3 appearanceUniProt predicts RIPK3 at 56.9 kDa, but no empirical band size is supplied; confirm a candidate band with appropriate antibody and sample controls.
| UniProt predicted mass | Places the reference band near 56.9 kDa without establishing its observed migration. |
| Splice isoform 1 | May migrate differently from other isoforms; its individual mass is not supplied. |
| Splice isoform 2 | May migrate differently from other isoforms; its individual mass is not supplied. |
| Splice isoform 3 | May migrate differently from other isoforms; its individual mass is not supplied. |
| Situation | Likely cause | Next action |
|---|---|---|
| No band in lysate | RIPK3 may be below detection in the sampled lysate. | Check loading and antibody performance with a validated RIPK3-positive lysate. |
| Band higher than expected | An isoform or phosphorylation state may alter migration; neither shift is established here. | Confirm identity with an independent RIPK3 antibody or RIPK3-depleted sample. |
| Band lower than expected | An alternative splice isoform is possible, but its mass is unknown. | Confirm identity with RIPK3 depletion and, if available, isoform-specific detection. |
| Multiple bands | Isoforms 1, 2, and 3 or different phosphorylation states could contribute. | Use RIPK3 depletion to identify specific bands; test phosphatase sensitivity if appropriate. |
| Weak or no signal | RIPK3 localization can shift toward the nucleus after influenza A infection. | If testing infected cytosolic fractions, also examine matched nuclear and whole-cell samples. |
Experiment evidence
Western blot images showing RIPK3 band
PA2242 · RIPK3
← swipe / scroll for more images →
Real WB data behind the band-size expectations in this section.
Sample controls for RIPK3 Western blot
🧪For positive controls for RIPK3 in Western blot, you can use a validated RIPK3-positive cell lysate, since the supplied HPA record identifies no positive tissue or cell line.
Positive control: No high/medium HPA tissue identified
Negative control: Suggested KO / knockdown lysate
Loading controls: Run GAPDH, β-actin, and a total-protein stain alongside the samples.
⚠️Feasibility: HPA provides no expression data here, so a positive lysate needs validation and a KO line provides the clearest negative control.
HPA tissue expression evidence for RIPK3
Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Higher expression tissues · candidate positive controls from IHC
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| No high/medium HPA tissues identified in the supplied evidence. | ||||
Lower expression tissues · IHC evidence, not confirmed WB-negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| No lower-expression tissue rows available in the supplied evidence. | ||||
Section 3
Advanced RIPK3 Western Blot Tips
Deeper troubleshooting and optimisation questions for RIPK3, answered from its protein features.
Where should the main RIPK3 band appear?
Band shift · The supplied predicted mass is 56.9 kDa. No observed band position is available, so use 56.9 kDa as a reference rather than an expected apparent mass.
Could RIPK3 isoforms produce different bands?
Isoforms · Three isoforms are listed. Isoform 2 replaces residues 220–518, and isoform 3 replaces residues 222–518, with shorter sequences. Their apparent band positions are not supplied; check which isoforms your antibody can detect before assigning extra bands.
Residues 1–219 are shared by the listed sequences. An epitope in that region could detect all three isoforms; an epitope within the replaced C-terminal region may distinguish them.
Residues 1–219 are shared by the listed sequences. An epitope in that region could detect all three isoforms; an epitope within the replaced C-terminal region may distinguish them.
Which RIPK3 phosphorylation sites matter when interpreting phospho-specific bands?
PTM · The listed UniProt coordinates are Ser2, Ser164, Thr182, Ser199, Ser227, Thr252, Ser299, Thr333, Ser389 and Thr401. Ser199 and Ser227 are annotated as phosphorylated by autocatalysis. Check the antibody’s residue-numbering convention against these UniProt coordinates before matching a phospho-specific signal.
RIPK3 has ten listed phosphorylation sites, but their presence alone does not establish a visible shift or explain a particular apparent mass. Compare the band with a total RIPK3 signal before assigning it to phosphorylation.
RIPK3 has ten listed phosphorylation sites, but their presence alone does not establish a visible shift or explain a particular apparent mass. Compare the band with a total RIPK3 signal before assigning it to phosphorylation.
Does this guide establish induction of RIPK3?
Induction · No general induction response is established by this guide. A pathway or gene-set association is not evidence of induction in a particular specimen. Verify the relevant treatment and control in a target-specific experiment.
How should transfer be checked for RIPK3?
Transfer · Standard workflow guidance: verify transfer efficiency for the intended target size before interpreting a weak signal. Use total-protein assessment and optimize transfer for the membrane, gel and apparatus; the labelled catalog values take precedence.
How should blocking be optimized?
Blocking · Standard workflow guidance: follow the PA2242 datasheet where specified. Otherwise compare 5% milk or 5% BSA in TBST; for a phospho-specific assay start with BSA. Optimize background and specific signal with matched controls.
How should RIPK3 bands be quantified across samples?
Quantitation · Specify whether the antibody measures total RIPK3 or a listed phosphosite. Because the three isoforms have different sequences, quantify corresponding bands consistently across samples and report which bands were included.
How could influenza A infection affect fractionated RIPK3 samples?
Interpretation · RIPK3 is annotated as mainly cytoplasmic, with nuclear presence in response to influenza A virus infection. That nuclear observation is annotated by similarity to another UniProt entry. If comparing fractions, assess both cytosolic and nuclear samples; the feature does not establish increased total RIPK3 abundance.
Check whether the antibody epitope lies in sequence shared by all three isoforms or in their differing C-terminal regions. The listed phosphorylation sites are another consideration, but neither isoform annotation nor modification-site presence alone identifies an observed band.
Check whether the antibody epitope lies in sequence shared by all three isoforms or in their differing C-terminal regions. The listed phosphorylation sites are another consideration, but neither isoform annotation nor modification-site presence alone identifies an observed band.
Boster reagents
RIPK3 Western Blot Antibodies
Catalog antibodies with Western blot application and product-specific WB images. Evaluate suitability with the reported sample, controls and experimental conditions.
Real WB data
Anti-RIP3/RIPK3 Antibody Picoband®
Cat # PA2242
PA2242 is an anti-RIP3/RIPK3 antibody listed for human reactivity. Its Western blot image shows PANC, SW620, SKOV-3, and M231 cell lysates. The supplied evidence does not include independent publication validation.
Which to pick: PA2242 is the only listed option. It has a Western blot image using four named cell lysates; choose it when its listed human reactivity and tested sample contexts fit your experiment.
Source: BosterBio RIPK3 gene-info card — filtered to Western-blot-capable antibodies; each card shows that product's actual WB validation figure.
References
- UniProt Consortium. UniProt entry Q9Y572.
- Human Protein Atlas. RIPK3 tissue expression.
- PMC11845712 — target-verified WB comparison
- PMC6768878 — target-verified WB comparison
- PMC12178437 — target-verified WB comparison